This moment not only celebrates our journey, but also consolidates our recent prestigious recognition as Europe's Leading Long-Term Growth Company in the Health Care & Life Sciences sector, according to the Financial Times and Statista rankings.

This achievement isn't just a number; it confirms that our strategic vision is winning, especially in the unique demographic context of Italy.

Italy, with one of the oldest populations in Europe, presents challenges, but we have transformed them into opportunities for growth and innovation. As our President of Kolinpharma^®, Rita Paola Petrelli, emphasized:

"The aging process is lengthening, the average age is rising. [...] This is why we develop effective nutraceuticals that truly support people's well-being and quality of life."

"This is our mission: not only to grow as a company (with revenue of €19 million last year), but also to actively contribute to the quality of life of the aging population and those who care for them," continues Rita Paola Petrelli.

The secret? A constant investment in Research and Development dedicated to creating nutraceuticals containing unique active ingredients, with scientifically studied efficacy, offering relief from age-related ailments such as joint pain, menopause, and cognitive decline.

A special thank you to the entire Kolinpharma^® team for their dedication every day to carrying out the company's mission.